In Its Second Phase, The Company Will Scale-up In A Modular Fashion With 50,000 Additional Square Feet In The Near-term.

On February 23, the company was also featured in a video profile and official announcement of the top-ranking stocks in each sector. Emerald Health is one of less than 40 licensed producers under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). According to Deloitte, the country’s cannabis sector could be worth more than $22.6 billion following the legalization of recreational marijuana. The lack of supplies to the large and growing market could create a shortfall over the coming years, particularly as the country begins exporting product around the world. The company is well underway with its first phase of expansion that will add 50,000 square feet of cultivation space and a state-of-the-art facility with anticipated capacity in excess of 5,000 kilograms per year. In its second phase, the company will scale-up in a modular fashion with 50,000 additional square feet in the near-term. Management anticipates that both phases will be completed in 2018 with sales commencing when licensing is completed. The company has the capacity to build out an aggregate one million square feet of total production space on its 32-acre Metro Vancouver property. At the same time, the company Marijuana Stocks continues to expand its genetic portfolio and develop its clinical programs. The staff is in the process of characterizing unique strains with high and desirable ratios of therapeutic cannabinoids while assembling a proven cultivation team to ultimately bring them to market. The company is also collaborating with leading physicians and researchers to design clinical studies to demonstrate the efficacy of its own products.

To read more visit

Share This Post

Recent Articles

Leave a Reply